Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Rubius Therapeutics announces preclinical data for RTX-224 » 07:45
11/12/21
11/12
07:45
11/12/21
07:45
RUBY

Rubius Therapeutics

$14.46 /

+0.42 (+2.99%)

Rubius Therapeutics…

Rubius Therapeutics announced the poster presentation of preclinical data for RTX-224, a broad immune costimulatory agonist for the treatment of cancer, at the Society for Immunotherapy of Cancer's 36th Annual Meeting which is being held from November 10-14, 2021, in Washington, D.C., and virtually. Poster Title: RTX-224, An Engineered Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune Cells in Blood and Spleen to Promote Tumor Growth Inhibition in Mice RTX-224 is an allogeneic cellular therapy product candidate that is engineered to express hundreds of thousands of copies of 4-1BB ligand and interleukin-12 on the cell surface. RTX-224 is designed as a broad immune agonist of both adaptive and innate responses, activating CD8+ and CD4+ T cells, promoting antigen presentation and activating and expanding NK cells. It is expected to produce a broad and potent anti-tumor T cell response, an innate immune response and have anti-tumor activity in those tumor types with known sensitivity to T cell killing, including tumor types with high mutational burden, PD-L1 expression and prior responsiveness to checkpoint inhibitors. Data Summary The mouse surrogate of RTX-224, mRBC-224, demonstrated potent anti-tumor activity in B16F10 melanoma models, intravenously and subcutaneously, that was associated with pharmacodynamic changes in the tumors, including activated CD8+ T cells, NK cells and macrophages. mRBC-224 distributed mainly in the spleen of tumor-bearing mice 24 hours after one dose. mRBC-224 treatment in mice promoted activation of NK cells, CD8+ T cells and monocytes/macrophages in the blood and spleen of naive and tumor-bearing mice. RTX-224 and mRBC-224 stimulate adaptive and innate immune responses. The combined enhancement of both adaptive and innate immune responses leads to a productive antitumor response as demonstrated in preclinical studies.

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$14.46 /

+0.42 (+2.99%)

RUBY Rubius Therapeutics
$14.46 /

+0.42 (+2.99%)

10/19/21 Morgan Stanley
Rubius Therapeutics assumed with an Equal Weight at Morgan Stanley
03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
RUBY Rubius Therapeutics
$14.46 /

+0.42 (+2.99%)

  • 17
    Mar
Earnings
Rubius Therapeutics reports Q3 EPS (55c), consensus (57c) » 16:50
11/08/21
11/08
16:50
11/08/21
16:50
RUBY

Rubius Therapeutics

$14.78 /

+0.08 (+0.54%)

As of September 30, cash…

As of September 30, cash and cash equivalents were $264M, compared to $176.3M in cash, cash equivalents and investments as of December 31, 2020. "With the clearance of our latest IND application for RTX-224, we will have three Red Cell Therapeutic product candidates for the potential treatment of cancer in the clinic, demonstrating continued strong execution across preclinical and clinical development as well as manufacturing," said Larry Turka, M.D., Chief Scientific Officer. "As shown in our preclinical studies, RTX-224 is designed to activate CD8+ and CD4+ T cells, promote antigen presentation and activate and expand NK cells to produce a broad and potent anti-tumor T cell response in solid tumor cancers with known sensitivity to T cell killing, including tumor types with high mutational burden, PD-L1 expression and prior responsiveness to checkpoint inhibitors."

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$14.78 /

+0.08 (+0.54%)

RUBY Rubius Therapeutics
$14.78 /

+0.08 (+0.54%)

10/19/21 Morgan Stanley
Rubius Therapeutics assumed with an Equal Weight at Morgan Stanley
03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
RUBY Rubius Therapeutics
$14.78 /

+0.08 (+0.54%)

  • 17
    Mar
Over a month ago
Initiation
Rubius Therapeutics assumed with an Equal Weight at Morgan Stanley » 08:41
10/19/21
10/19
08:41
10/19/21
08:41
RUBY

Rubius Therapeutics

$15.99 /

-0.28 (-1.72%)

Morgan Stanley analyst…

Morgan Stanley analyst Jeffrey Hung assumed coverage of Rubius Therapeutics with an Equal Weight rating with a price target of $22, down from $25. Initial Phase 1 data for lead oncology asset RTX-240 showed signs of activity, but Hung believes it is still too early to draw firm conclusions based on the limited numbers of patients for each tumor type, he said.

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$15.99 /

-0.28 (-1.72%)

RUBY Rubius Therapeutics
$15.99 /

-0.28 (-1.72%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
RUBY Rubius Therapeutics
$15.99 /

-0.28 (-1.72%)

  • 17
    Mar
Hot Stocks
Rubius Therapeutics announces preclinical data for RTX-224 » 08:17
10/01/21
10/01
08:17
10/01/21
08:17
RUBY

Rubius Therapeutics

$17.87 /

+0.39 (+2.23%)

Rubius Therapeutics…

Rubius Therapeutics announced it will present preclinical data for RTX-224, a broad immune costimulatory agonist for the treatment of cancer, at the upcoming Society for Immunotherapy of Cancer's 36th Annual Meeting which is being held from November 10-14, 2021, in Washington, D.C., and virtually. RTX-224 is an allogeneic cellular therapy that is engineered to express hundreds of thousands of copies of 4-1BB ligand and interleukin-12 on the cell surface. RTX-224 is designed as a broad immune agonist of both adaptive and innate responses, activating CD8+ and CD4+ T cells, promoting antigen presentation and activating and expanding NK cells. It is expected to produce a broad and potent anti-tumor T cell response, an innate immune response and have anti-tumor activity in those tumor types with known sensitivity to T cell killing, including tumor types with high mutational burden, PD-L1 expression and prior responsiveness to checkpoint inhibitors.

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$17.87 /

+0.39 (+2.23%)

RUBY Rubius Therapeutics
$17.87 /

+0.39 (+2.23%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$17.87 /

+0.39 (+2.23%)

  • 17
    Mar
Conference/Events
H.C. Wainwright to hold a virtual conference » 04:55
09/15/21
09/15
04:55
09/15/21
04:55
ABUS

Arbutus Biopharma

$4.25 /

-0.005 (-0.12%)

, ACER

Acer Therapeutics

$2.53 /

-0.1 (-3.80%)

, ACET

Adicet Bio

$7.28 /

-0.47 (-6.06%)

, CIDM

Cinedigm

$2.16 /

+0.06 (+2.86%)

, TMDI

Titan Medical

$1.59 /

-0.025 (-1.55%)

, SLGG

Super League Gaming

$3.60 /

-0.21 (-5.51%)

, SLRX

Salarius Pharmaceuticals

$1.03 /

+ (+0.00%)

, SMLR

Semler Scientific

$106.60 /

-0.43 (-0.40%)

, ZYNE

Zynerba

$4.31 /

-0.135 (-3.04%)

, TARA

Protara Therapeutics

$7.19 /

-0.46 (-6.01%)

, TCON

Tracon Pharmaceuticals

$3.73 /

-0.11 (-2.86%)

, RUBY

Rubius Therapeutics

$19.44 /

-0.68 (-3.38%)

, PLSE

Pulse Biosciences

$20.46 /

-0.26 (-1.25%)

, PNT

Point Biopharma

$9.34 /

+0.31 (+3.43%)

, IMRA

Imara

$4.12 /

-0.14 (-3.29%)

, IMAB

I-Mab

$68.57 /

+0.32 (+0.47%)

, KBNT

Kubient

$3.50 /

+0.07 (+2.04%)

, LPTX

Leap Therapeutics

$1.79 /

+0.01 (+0.56%)

, LUMO

Lumos Pharma

$10.10 /

-0.45 (-4.27%)

, LYRA

Lyra Therapeutics

$8.18 /

-0.37 (-4.33%)

, EDAP

EDAP TMS

$6.25 /

+0.255 (+4.25%)

, EXEL

Exelixis

$20.14 /

-0.11 (-0.54%)

, GMTX

Gemini Therapeutics

$4.54 /

-0.045 (-0.98%)

, BLU

Bellus Health

$5.56 /

+0.79 (+16.56%)

, CGRN

Capstone Green Energy

$4.45 /

-0.06 (-1.33%)

, DYAI

Dyadic International

$5.34 /

-0.41 (-7.13%)

, AGRI

AgriFORCE Growing Systems

$2.32 /

-0.19 (-7.57%)

, ANEB

Anebulo Pharmaceuticals

$6.96 /

-0.06 (-0.85%)

, VIVE

Viveve

$2.39 /

-0.07 (-2.85%)

, ZIOP

Ziopharm

$1.63 /

-0.195 (-10.68%)

23rd Annual Global…

23rd Annual Global Investment Virtual Conference to be held on September 13-15.Webcast Link

ShowHide Related Items >><<
ZYNE Zynerba
$4.31 /

-0.135 (-3.04%)

ZIOP Ziopharm
$1.63 /

-0.195 (-10.68%)

VIVE Viveve
$2.39 /

-0.07 (-2.85%)

TMDI Titan Medical
$1.59 /

-0.025 (-1.55%)

TCON Tracon Pharmaceuticals
$3.73 /

-0.11 (-2.86%)

TARA Protara Therapeutics
$7.19 /

-0.46 (-6.01%)

SLRX Salarius Pharmaceuticals
$1.03 /

+ (+0.00%)

SLGG Super League Gaming
$3.60 /

-0.21 (-5.51%)

RUBY Rubius Therapeutics
$19.44 /

-0.68 (-3.38%)

PNT Point Biopharma
$9.34 /

+0.31 (+3.43%)

PLSE Pulse Biosciences
$20.46 /

-0.26 (-1.25%)

LYRA Lyra Therapeutics
$8.18 /

-0.37 (-4.33%)

LUMO Lumos Pharma
$10.10 /

-0.45 (-4.27%)

LPTX Leap Therapeutics
$1.79 /

+0.01 (+0.56%)

KBNT Kubient
$3.50 /

+0.07 (+2.04%)

IMRA Imara
$4.12 /

-0.14 (-3.29%)

IMAB I-Mab
$68.57 /

+0.32 (+0.47%)

GMTX Gemini Therapeutics
$4.54 /

-0.045 (-0.98%)

EXEL Exelixis
$20.14 /

-0.11 (-0.54%)

EDAP EDAP TMS
$6.25 /

+0.255 (+4.25%)

DYAI Dyadic International
$5.34 /

-0.41 (-7.13%)

CIDM Cinedigm
$2.16 /

+0.06 (+2.86%)

CGRN Capstone Green Energy
$4.45 /

-0.06 (-1.33%)

BLU Bellus Health
$5.56 /

+0.79 (+16.56%)

AGRI AgriFORCE Growing Systems
$2.32 /

-0.19 (-7.57%)

ACET Adicet Bio
$7.28 /

-0.47 (-6.06%)

ACER Acer Therapeutics
$2.53 /

-0.1 (-3.80%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
ACER Acer Therapeutics
$2.53 /

-0.1 (-3.80%)

06/10/21 William Blair
Acer's increased pipeline visibility is encouraging, says William Blair
ACET Adicet Bio
$7.28 /

-0.47 (-6.06%)

05/17/21 BTIG
Adicet Bio initiated with a Buy at BTIG
05/17/21 BTIG
Adicet Bio initiated with a Buy at BTIG
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 JonesTrading
Adicet Bio initiated with a Buy at JonesTrading
CIDM Cinedigm
$2.16 /

+0.06 (+2.86%)

08/02/21 Alliance Global Partners
Cinedigm price target raised to $3.25 from $3.00 at Alliance Global Partners
05/12/21 Alliance Global Partners
Alliance Global Partners bullish on Cinedigm, sees Roku among catalysts
01/21/21 Alliance Global Partners
Cinedigm price target raised to $3 from $2 at Alliance Global Partners
10/16/20 Alliance Global Partners
Cinedigm initiated with a Buy at Alliance Global Partners
TMDI Titan Medical
$1.59 /

-0.025 (-1.55%)

04/06/21 Oppenheimer
Opco starts 'attractive micro-cap play' Titan Medical with Outperform
04/06/21 Oppenheimer
Titan Medical initiated with an Outperform at Oppenheimer
SLGG Super League Gaming
$3.60 /

-0.21 (-5.51%)

05/27/21 H.C. Wainwright
Super League Gaming initiated with a Buy at H.C. Wainwright
03/01/21 Maxim
Super League Gaming initiated with a Buy at Maxim
03/01/21 Maxim
Super League Gaming initiated with a Buy at Maxim
02/09/21 Alliance Global Partners
Super League downgraded on 'rich' valuation at Alliance Global
SLRX Salarius Pharmaceuticals
$1.03 /

+ (+0.00%)

08/25/21
Fly Intel: Top five analyst initiations
08/25/21 H.C. Wainwright
Salarius Pharmaceuticals initiated with a Buy at H.C. Wainwright
SMLR Semler Scientific
$106.60 /

-0.43 (-0.40%)

05/04/21 B. Riley
Semler Scientific price target raised to $151 from $147 at B. Riley
04/27/21 B. Riley
Semler Scientific transferred with Buy, $147 target at B. Riley
03/02/21 B. Riley
Semler Scientific price target raised to $147 from $121 at B. Riley Securities
02/25/21 B. Riley
Semler Scientific price target raised to $121 from $100 at B. Riley Securities
ZYNE Zynerba
$4.31 /

-0.135 (-3.04%)

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
03/10/21 Roth Capital
Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
TARA Protara Therapeutics
$7.19 /

-0.46 (-6.01%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
TCON Tracon Pharmaceuticals
$3.73 /

-0.11 (-2.86%)

06/04/21
Fly Intel: Top five analyst initiations
06/04/21 Alliance Global Partners
Tracon Pharmaceuticals initiated with a Buy at Alliance Global Partners
04/16/21 BTIG
BTIG upgrades Tracon to Buy with $14 target on Envafolimab progress
04/16/21 BTIG
Tracon Pharmaceuticals upgraded to Buy from Neutral at BTIG
RUBY Rubius Therapeutics
$19.44 /

-0.68 (-3.38%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
PLSE Pulse Biosciences
$20.46 /

-0.26 (-1.25%)

07/26/21 Stephens
Pulse Biosciences a 'compelling and durable story,' says Stephens
07/26/21 Stephens
Pulse Biosciences initiated with an Overweight at Stephens
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
PNT Point Biopharma
$9.34 /

+0.31 (+3.43%)

07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
07/26/21 Piper Sandler
Point Biopharma initiated with an Overweight at Piper Sandler
IMRA Imara
$4.12 /

-0.14 (-3.29%)

08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
IMAB I-Mab
$68.57 /

+0.32 (+0.47%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
KBNT Kubient
$3.50 /

+0.07 (+2.04%)

08/17/21 Maxim
Kubient price target lowered to $9 from $13 at Maxim
03/26/21 Maxim
Kubient price target raised to $13 from $10 at Maxim
10/27/20 Maxim
Kubient initiated with a Buy at Maxim
LPTX Leap Therapeutics
$1.79 /

+0.01 (+0.56%)

09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
05/17/21 Piper Sandler
Leap Therapeutics price target lowered to $4 from $6 at Piper Sandler
LUMO Lumos Pharma
$10.10 /

-0.45 (-4.27%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
LYRA Lyra Therapeutics
$8.18 /

-0.37 (-4.33%)

12/07/20 BofA
Lyra Therapeutics price target raised to $26 from $19 at BofA
EDAP EDAP TMS
$6.25 /

+0.255 (+4.25%)

04/28/21
Fly Intel: Top five analyst initiations
04/28/21 Piper Sandler
EDAP TMS initiated with an Overweight at Piper Sandler
04/01/21 H.C. Wainwright
EDAP TMS price target raised to $12 from $10 at H.C. Wainwright
01/25/21 Lake Street
EDAP TMS initiated with a Buy at Lake Street
EXEL Exelixis
$20.14 /

-0.11 (-0.54%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
GMTX Gemini Therapeutics
$4.54 /

-0.045 (-0.98%)

06/23/21 Stifel
Gemini's negative stock reaction to GEM103 data overdone, says Stifel
04/08/21 SVB Leerink
SVB Leerink bullish on Gemini Therapeutics, initiates with an Outperform
04/08/21 SVB Leerink
Gemini Therapeutics initiated with an Outperform at SVB Leerink
03/03/21 Jefferies
Gemini Therapeutics initiated with a Buy at Jefferies
BLU Bellus Health
$5.56 /

+0.79 (+16.56%)

09/14/21 BTIG
Bellus Health price target raised to $13 from $9 at BTIG
09/14/21 H.C. Wainwright
Bellus Health price target raised to $14 from $10 at H.C. Wainwright
07/29/21 BTIG
Bellus Health initiated with a Buy at BTIG
01/29/21 RBC Capital
Bellus Health initiated with an Outperform at RBC Capital
CGRN Capstone Green Energy
$4.45 /

-0.06 (-1.33%)

DYAI Dyadic International
$5.34 /

-0.41 (-7.13%)

AGRI AgriFORCE Growing Systems
$2.32 /

-0.19 (-7.57%)

ANEB Anebulo Pharmaceuticals
$6.96 /

-0.06 (-0.85%)

05/25/21 Benchmark
Anebulo Pharmaceuticals initiated with a Buy at Benchmark
VIVE Viveve
$2.39 /

-0.07 (-2.85%)

01/29/21 Alliance Global Partners
Viveve initiated with a Buy at Alliance Global Partners
ZIOP Ziopharm
$1.63 /

-0.195 (-10.68%)

08/10/21 Raymond James
Ziopharm downgraded to Market Perform from Outperform at Raymond James
08/10/21 Lake Street
Ziopharm price target lowered to $3.50 from $7 at Lake Street
08/10/21 Raymond James
Ziopharm downgraded to Market Perform from Outperform at Raymond James
08/09/21 Raymond James
Ziopharm downgraded to Market Perform from Outperform at Raymond James
ZYNE Zynerba
$4.31 /

-0.135 (-3.04%)

TCON Tracon Pharmaceuticals
$3.73 /

-0.11 (-2.86%)

TARA Protara Therapeutics
$7.19 /

-0.46 (-6.01%)

SLRX Salarius Pharmaceuticals
$1.03 /

+ (+0.00%)

RUBY Rubius Therapeutics
$19.44 /

-0.68 (-3.38%)

PNT Point Biopharma
$9.34 /

+0.31 (+3.43%)

PLSE Pulse Biosciences
$20.46 /

-0.26 (-1.25%)

LYRA Lyra Therapeutics
$8.18 /

-0.37 (-4.33%)

LUMO Lumos Pharma
$10.10 /

-0.45 (-4.27%)

LPTX Leap Therapeutics
$1.79 /

+0.01 (+0.56%)

KBNT Kubient
$3.50 /

+0.07 (+2.04%)

IMRA Imara
$4.12 /

-0.14 (-3.29%)

GMTX Gemini Therapeutics
$4.54 /

-0.045 (-0.98%)

EXEL Exelixis
$20.14 /

-0.11 (-0.54%)

EDAP EDAP TMS
$6.25 /

+0.255 (+4.25%)

CIDM Cinedigm
$2.16 /

+0.06 (+2.86%)

ACET Adicet Bio
$7.28 /

-0.47 (-6.06%)

ACER Acer Therapeutics
$2.53 /

-0.1 (-3.80%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

  • 14
    Jul
  • 18
    Jun
  • 07
    May
  • 23
    Apr
  • 17
    Mar
  • 04
    Mar
  • 10
    Feb
  • 09
    Feb
  • 13
    Jan
  • 06
    Jan
  • 23
    Dec
  • 20
    Oct
  • 22
    Sep
  • 24
    Sep
ZYNE Zynerba
$4.31 /

-0.135 (-3.04%)

IMAB I-Mab
$68.57 /

+0.32 (+0.47%)

ZYNE Zynerba
$4.31 /

-0.135 (-3.04%)

TCON Tracon Pharmaceuticals
$3.73 /

-0.11 (-2.86%)

SLRX Salarius Pharmaceuticals
$1.03 /

+ (+0.00%)

RUBY Rubius Therapeutics
$19.44 /

-0.68 (-3.38%)

LYRA Lyra Therapeutics
$8.18 /

-0.37 (-4.33%)

LUMO Lumos Pharma
$10.10 /

-0.45 (-4.27%)

LPTX Leap Therapeutics
$1.79 /

+0.01 (+0.56%)

IMRA Imara
$4.12 /

-0.14 (-3.29%)

GMTX Gemini Therapeutics
$4.54 /

-0.045 (-0.98%)

EXEL Exelixis
$20.14 /

-0.11 (-0.54%)

EDAP EDAP TMS
$6.25 /

+0.255 (+4.25%)

CIDM Cinedigm
$2.16 /

+0.06 (+2.86%)

CGRN Capstone Green Energy
$4.45 /

-0.06 (-1.33%)

ANEB Anebulo Pharmaceuticals
$6.96 /

-0.06 (-0.85%)

AGRI AgriFORCE Growing Systems
$2.32 /

-0.19 (-7.57%)

ACET Adicet Bio
$7.28 /

-0.47 (-6.06%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

ZYNE Zynerba
$4.31 /

-0.135 (-3.04%)

TARA Protara Therapeutics
$7.19 /

-0.46 (-6.01%)

KBNT Kubient
$3.50 /

+0.07 (+2.04%)

IMRA Imara
$4.12 /

-0.14 (-3.29%)

ACET Adicet Bio
$7.28 /

-0.47 (-6.06%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

Conference/Events
H.C. Wainwright to hold a virtual conference » 09:30
09/14/21
09/14
09:30
09/14/21
09:30
ABUS

Arbutus Biopharma

$4.25 /

-0.145 (-3.30%)

, ACER

Acer Therapeutics

$2.61 /

-0.09 (-3.33%)

, ACET

Adicet Bio

$7.52 /

-0.16 (-2.08%)

, CIDM

Cinedigm

$2.10 /

+0.01 (+0.48%)

, TMDI

Titan Medical

$1.62 /

+0.05 (+3.19%)

, SLGG

Super League Gaming

$3.81 /

-0.08 (-2.06%)

, SLRX

Salarius Pharmaceuticals

$1.03 /

-0.025 (-2.37%)

, SMLR

Semler Scientific

$107.03 /

-2.72 (-2.48%)

, ZYNE

Zynerba

$4.44 /

-0.035 (-0.78%)

, TARA

Protara Therapeutics

$7.64 /

-0.12 (-1.55%)

, TCON

Tracon Pharmaceuticals

$3.85 /

-0.02 (-0.52%)

, RUBY

Rubius Therapeutics

$20.12 /

-0.83 (-3.96%)

, PLSE

Pulse Biosciences

$20.78 /

-0.14 (-0.67%)

, PNT

Point Biopharma

$9.15 /

-2.33 (-20.30%)

, IMRA

Imara

$4.26 /

-0.14 (-3.18%)

, IMAB

I-Mab

$68.25 /

-3.75 (-5.21%)

, KBNT

Kubient

$3.43 /

+0.13 (+3.94%)

, LPTX

Leap Therapeutics

$1.78 /

+0.31 (+21.16%)

, LUMO

Lumos Pharma

$10.64 /

-0.6 (-5.34%)

, LYRA

Lyra Therapeutics

$8.45 /

+ (+0.00%)

, EDAP

EDAP TMS

$6.00 /

+0.005 (+0.08%)

, EXEL

Exelixis

$20.25 /

+0.275 (+1.38%)

, GMTX

Gemini Therapeutics

$4.59 /

-0.1 (-2.13%)

, BLU

Bellus Health

$4.77 /

+0.84 (+21.37%)

, CGRN

Capstone Green Energy

$4.52 /

+0.01 (+0.22%)

, DYAI

Dyadic International

$5.78 /

+0.04 (+0.70%)

, AGRI

AgriFORCE Growing Systems

$2.51 /

-0.04 (-1.57%)

, ANEB

Anebulo Pharmaceuticals

$7.02 /

+0.12 (+1.74%)

, VIVE

Viveve

$2.46 /

-0.03 (-1.20%)

, ZIOP

Ziopharm

$1.83 /

-0.075 (-3.95%)

23rd Annual Global…

23rd Annual Global Investment Virtual Conference to be held on September 13-15.Webcast Link

ShowHide Related Items >><<
ZYNE Zynerba
$4.44 /

-0.035 (-0.78%)

ZIOP Ziopharm
$1.83 /

-0.075 (-3.95%)

VIVE Viveve
$2.46 /

-0.03 (-1.20%)

TMDI Titan Medical
$1.62 /

+0.05 (+3.19%)

TCON Tracon Pharmaceuticals
$3.85 /

-0.02 (-0.52%)

TARA Protara Therapeutics
$7.64 /

-0.12 (-1.55%)

SLRX Salarius Pharmaceuticals
$1.03 /

-0.025 (-2.37%)

SLGG Super League Gaming
$3.81 /

-0.08 (-2.06%)

RUBY Rubius Therapeutics
$20.12 /

-0.83 (-3.96%)

PNT Point Biopharma
$9.15 /

-2.33 (-20.30%)

PLSE Pulse Biosciences
$20.78 /

-0.14 (-0.67%)

LYRA Lyra Therapeutics
$8.45 /

+ (+0.00%)

LUMO Lumos Pharma
$10.64 /

-0.6 (-5.34%)

LPTX Leap Therapeutics
$1.78 /

+0.31 (+21.16%)

KBNT Kubient
$3.43 /

+0.13 (+3.94%)

IMRA Imara
$4.26 /

-0.14 (-3.18%)

IMAB I-Mab
$68.25 /

-3.75 (-5.21%)

GMTX Gemini Therapeutics
$4.59 /

-0.1 (-2.13%)

EXEL Exelixis
$20.25 /

+0.275 (+1.38%)

EDAP EDAP TMS
$6.00 /

+0.005 (+0.08%)

DYAI Dyadic International
$5.78 /

+0.04 (+0.70%)

CIDM Cinedigm
$2.10 /

+0.01 (+0.48%)

CGRN Capstone Green Energy
$4.52 /

+0.01 (+0.22%)

BLU Bellus Health
$4.77 /

+0.84 (+21.37%)

AGRI AgriFORCE Growing Systems
$2.51 /

-0.04 (-1.57%)

ACET Adicet Bio
$7.52 /

-0.16 (-2.08%)

ACER Acer Therapeutics
$2.61 /

-0.09 (-3.33%)

ABUS Arbutus Biopharma
$4.25 /

-0.145 (-3.30%)

ABUS Arbutus Biopharma
$4.25 /

-0.145 (-3.30%)

06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
ACER Acer Therapeutics
$2.61 /

-0.09 (-3.33%)

06/10/21 William Blair
Acer's increased pipeline visibility is encouraging, says William Blair
ACET Adicet Bio
$7.52 /

-0.16 (-2.08%)

05/17/21 BTIG
Adicet Bio initiated with a Buy at BTIG
05/17/21 BTIG
Adicet Bio initiated with a Buy at BTIG
04/29/21
Fly Intel: Top five analyst initiations
04/29/21 JonesTrading
Adicet Bio initiated with a Buy at JonesTrading
CIDM Cinedigm
$2.10 /

+0.01 (+0.48%)

08/02/21 Alliance Global Partners
Cinedigm price target raised to $3.25 from $3.00 at Alliance Global Partners
05/12/21 Alliance Global Partners
Alliance Global Partners bullish on Cinedigm, sees Roku among catalysts
01/21/21 Alliance Global Partners
Cinedigm price target raised to $3 from $2 at Alliance Global Partners
10/16/20 Alliance Global Partners
Cinedigm initiated with a Buy at Alliance Global Partners
TMDI Titan Medical
$1.62 /

+0.05 (+3.19%)

04/06/21 Oppenheimer
Opco starts 'attractive micro-cap play' Titan Medical with Outperform
04/06/21 Oppenheimer
Titan Medical initiated with an Outperform at Oppenheimer
SLGG Super League Gaming
$3.81 /

-0.08 (-2.06%)

05/27/21 H.C. Wainwright
Super League Gaming initiated with a Buy at H.C. Wainwright
03/01/21 Maxim
Super League Gaming initiated with a Buy at Maxim
03/01/21 Maxim
Super League Gaming initiated with a Buy at Maxim
02/09/21 Alliance Global Partners
Super League downgraded on 'rich' valuation at Alliance Global
SLRX Salarius Pharmaceuticals
$1.03 /

-0.025 (-2.37%)

08/25/21
Fly Intel: Top five analyst initiations
08/25/21 H.C. Wainwright
Salarius Pharmaceuticals initiated with a Buy at H.C. Wainwright
SMLR Semler Scientific
$107.03 /

-2.72 (-2.48%)

05/04/21 B. Riley
Semler Scientific price target raised to $151 from $147 at B. Riley
04/27/21 B. Riley
Semler Scientific transferred with Buy, $147 target at B. Riley
03/02/21 B. Riley
Semler Scientific price target raised to $147 from $121 at B. Riley Securities
02/25/21 B. Riley
Semler Scientific price target raised to $121 from $100 at B. Riley Securities
ZYNE Zynerba
$4.44 /

-0.035 (-0.78%)

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
05/06/21 Cantor Fitzgerald
Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
03/10/21 Roth Capital
Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
TARA Protara Therapeutics
$7.64 /

-0.12 (-1.55%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
TCON Tracon Pharmaceuticals
$3.85 /

-0.02 (-0.52%)

06/04/21
Fly Intel: Top five analyst initiations
06/04/21 Alliance Global Partners
Tracon Pharmaceuticals initiated with a Buy at Alliance Global Partners
04/16/21 BTIG
BTIG upgrades Tracon to Buy with $14 target on Envafolimab progress
04/16/21 BTIG
Tracon Pharmaceuticals upgraded to Buy from Neutral at BTIG
RUBY Rubius Therapeutics
$20.12 /

-0.83 (-3.96%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
PLSE Pulse Biosciences
$20.78 /

-0.14 (-0.67%)

07/26/21 Stephens
Pulse Biosciences a 'compelling and durable story,' says Stephens
07/26/21 Stephens
Pulse Biosciences initiated with an Overweight at Stephens
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
PNT Point Biopharma
$9.15 /

-2.33 (-20.30%)

07/29/21 Cowen
Cowen starts Point Biopharma at Outperform
07/29/21 Cowen
Point Biopharma initiated with an Outperform at Cowen
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
07/26/21 Piper Sandler
Point Biopharma initiated with an Overweight at Piper Sandler
IMRA Imara
$4.26 /

-0.14 (-3.18%)

08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
IMAB I-Mab
$68.25 /

-3.75 (-5.21%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
KBNT Kubient
$3.43 /

+0.13 (+3.94%)

08/17/21 Maxim
Kubient price target lowered to $9 from $13 at Maxim
03/26/21 Maxim
Kubient price target raised to $13 from $10 at Maxim
10/27/20 Maxim
Kubient initiated with a Buy at Maxim
LPTX Leap Therapeutics
$1.78 /

+0.31 (+21.16%)

09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
05/17/21 Piper Sandler
Leap Therapeutics price target lowered to $4 from $6 at Piper Sandler
LUMO Lumos Pharma
$10.64 /

-0.6 (-5.34%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
LYRA Lyra Therapeutics
$8.45 /

+ (+0.00%)

12/07/20 BofA
Lyra Therapeutics price target raised to $26 from $19 at BofA
EDAP EDAP TMS
$6.00 /

+0.005 (+0.08%)

04/28/21
Fly Intel: Top five analyst initiations
04/28/21 Piper Sandler
EDAP TMS initiated with an Overweight at Piper Sandler
04/01/21 H.C. Wainwright
EDAP TMS price target raised to $12 from $10 at H.C. Wainwright
01/25/21 Lake Street
EDAP TMS initiated with a Buy at Lake Street
EXEL Exelixis
$20.25 /

+0.275 (+1.38%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
GMTX Gemini Therapeutics
$4.59 /

-0.1 (-2.13%)

06/23/21 Stifel
Gemini's negative stock reaction to GEM103 data overdone, says Stifel
04/08/21 SVB Leerink
SVB Leerink bullish on Gemini Therapeutics, initiates with an Outperform
04/08/21 SVB Leerink
Gemini Therapeutics initiated with an Outperform at SVB Leerink
03/03/21 Jefferies
Gemini Therapeutics initiated with a Buy at Jefferies
BLU Bellus Health
$4.77 /

+0.84 (+21.37%)

09/14/21 BTIG
Bellus Health price target raised to $13 from $9 at BTIG
09/14/21 H.C. Wainwright
Bellus Health price target raised to $14 from $10 at H.C. Wainwright
07/29/21 BTIG
Bellus Health initiated with a Buy at BTIG
01/29/21 RBC Capital
Bellus Health initiated with an Outperform at RBC Capital
CGRN Capstone Green Energy
$4.52 /

+0.01 (+0.22%)

DYAI Dyadic International
$5.78 /

+0.04 (+0.70%)

AGRI AgriFORCE Growing Systems
$2.51 /

-0.04 (-1.57%)

ANEB Anebulo Pharmaceuticals
$7.02 /

+0.12 (+1.74%)

05/25/21 Benchmark
Anebulo Pharmaceuticals initiated with a Buy at Benchmark
VIVE Viveve
$2.46 /

-0.03 (-1.20%)

01/29/21 Alliance Global Partners
Viveve initiated with a Buy at Alliance Global Partners
ZIOP Ziopharm
$1.83 /

-0.075 (-3.95%)

08/10/21 Raymond James
Ziopharm downgraded to Market Perform from Outperform at Raymond James
08/10/21 Lake Street
Ziopharm price target lowered to $3.50 from $7 at Lake Street
08/10/21 Raymond James
Ziopharm downgraded to Market Perform from Outperform at Raymond James
08/09/21 Raymond James
Ziopharm downgraded to Market Perform from Outperform at Raymond James
ZYNE Zynerba
$4.44 /

-0.035 (-0.78%)

TCON Tracon Pharmaceuticals
$3.85 /

-0.02 (-0.52%)

TARA Protara Therapeutics
$7.64 /

-0.12 (-1.55%)

SLRX Salarius Pharmaceuticals
$1.03 /

-0.025 (-2.37%)

RUBY Rubius Therapeutics
$20.12 /

-0.83 (-3.96%)

PNT Point Biopharma
$9.15 /

-2.33 (-20.30%)

PLSE Pulse Biosciences
$20.78 /

-0.14 (-0.67%)

LYRA Lyra Therapeutics
$8.45 /

+ (+0.00%)

LUMO Lumos Pharma
$10.64 /

-0.6 (-5.34%)

LPTX Leap Therapeutics
$1.78 /

+0.31 (+21.16%)

KBNT Kubient
$3.43 /

+0.13 (+3.94%)

IMRA Imara
$4.26 /

-0.14 (-3.18%)

GMTX Gemini Therapeutics
$4.59 /

-0.1 (-2.13%)

EXEL Exelixis
$20.25 /

+0.275 (+1.38%)

EDAP EDAP TMS
$6.00 /

+0.005 (+0.08%)

CIDM Cinedigm
$2.10 /

+0.01 (+0.48%)

ACET Adicet Bio
$7.52 /

-0.16 (-2.08%)

ACER Acer Therapeutics
$2.61 /

-0.09 (-3.33%)

ABUS Arbutus Biopharma
$4.25 /

-0.145 (-3.30%)

  • 14
    Jul
  • 18
    Jun
  • 07
    May
  • 23
    Apr
  • 17
    Mar
  • 04
    Mar
  • 10
    Feb
  • 09
    Feb
  • 13
    Jan
  • 06
    Jan
  • 23
    Dec
  • 20
    Oct
  • 22
    Sep
  • 24
    Sep
ZYNE Zynerba
$4.44 /

-0.035 (-0.78%)

IMAB I-Mab
$68.25 /

-3.75 (-5.21%)

ZYNE Zynerba
$4.44 /

-0.035 (-0.78%)

TCON Tracon Pharmaceuticals
$3.85 /

-0.02 (-0.52%)

SLRX Salarius Pharmaceuticals
$1.03 /

-0.025 (-2.37%)

RUBY Rubius Therapeutics
$20.12 /

-0.83 (-3.96%)

LYRA Lyra Therapeutics
$8.45 /

+ (+0.00%)

LUMO Lumos Pharma
$10.64 /

-0.6 (-5.34%)

LPTX Leap Therapeutics
$1.78 /

+0.31 (+21.16%)

IMRA Imara
$4.26 /

-0.14 (-3.18%)

GMTX Gemini Therapeutics
$4.59 /

-0.1 (-2.13%)

EXEL Exelixis
$20.25 /

+0.275 (+1.38%)

EDAP EDAP TMS
$6.00 /

+0.005 (+0.08%)

CIDM Cinedigm
$2.10 /

+0.01 (+0.48%)

CGRN Capstone Green Energy
$4.52 /

+0.01 (+0.22%)

ANEB Anebulo Pharmaceuticals
$7.02 /

+0.12 (+1.74%)

AGRI AgriFORCE Growing Systems
$2.51 /

-0.04 (-1.57%)

ACET Adicet Bio
$7.52 /

-0.16 (-2.08%)

ABUS Arbutus Biopharma
$4.25 /

-0.145 (-3.30%)

ZYNE Zynerba
$4.44 /

-0.035 (-0.78%)

TARA Protara Therapeutics
$7.64 /

-0.12 (-1.55%)

KBNT Kubient
$3.43 /

+0.13 (+3.94%)

IMRA Imara
$4.26 /

-0.14 (-3.18%)

ACET Adicet Bio
$7.52 /

-0.16 (-2.08%)

ABUS Arbutus Biopharma
$4.25 /

-0.145 (-3.30%)

Hot Stocks
Rubius Therapeutics appoints Jim Jogerst as CBO » 08:11
08/30/21
08/30
08:11
08/30/21
08:11
RUBY

Rubius Therapeutics

$22.75 /

+1.775 (+8.46%)

Rubius Therapeutics…

Rubius Therapeutics announced the appointment of Jim Jogerst as chief business officer. He will oversee business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius' overall corporate strategy. Jim joins Rubius from Janssen Pharmaceuticals, where he led licensing transactions in the company's Infectious Diseases and Vaccines business.

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$22.75 /

+1.775 (+8.46%)

RUBY Rubius Therapeutics
$22.75 /

+1.775 (+8.46%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$22.75 /

+1.775 (+8.46%)

  • 17
    Mar
RUBY Rubius Therapeutics
$22.75 /

+1.775 (+8.46%)

Over a quarter ago
Hot Stocks
Rubius Therapeutics anticipated 2021 catalysts, objectives » 08:04
08/09/21
08/09
08:04
08/09/21
08:04
RUBY

Rubius Therapeutics

$21.63 /

-0.47 (-2.13%)

Present additional…

Present additional clinical data from the RTX-240 solid tumor Phase 1 clinical trial at the end of 2021 or during the first quarter of 2022; select specific solid tumor types that will be pursued in the Phase 2 expansion cohort of RTX-240; report initial clinical data from the Phase 1 arm of the RTX-240 clinical trial in relapsed/refractory AML; report initial Phase 1 clinical data from RTX-321 for the treatment of HPV 16-positive cancers by the first quarter of 2022; and submit an Investigational New Drug Application for RTX-224 by year-end.

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$21.63 /

-0.47 (-2.13%)

RUBY Rubius Therapeutics
$21.63 /

-0.47 (-2.13%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$21.63 /

-0.47 (-2.13%)

  • 17
    Mar
RUBY Rubius Therapeutics
$21.63 /

-0.47 (-2.13%)

Earnings
Rubius Therapeutics reports Q2 EPS (56c), consensus (49c) » 08:04
08/09/21
08/09
08:04
08/09/21
08:04
RUBY

Rubius Therapeutics

$21.63 /

-0.47 (-2.13%)

"During the quarter,…

"During the quarter, we continued to make excellent progress in advancing our fully owned oncology pipeline," said Pablo Cagnoni, M.D., President and Chief Executive Officer. "Given the favorable emerging safety profile and promising initial clinical activity reported for RTX-240, we initiated a combination Phase 1 arm with pembrolizumab with the goal of providing benefit to patients with cancers that have relapsed or are refractory after treatment with anti-PD-1 or PD-L1 antibodies."

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$21.63 /

-0.47 (-2.13%)

RUBY Rubius Therapeutics
$21.63 /

-0.47 (-2.13%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$21.63 /

-0.47 (-2.13%)

  • 17
    Mar
RUBY Rubius Therapeutics
$21.63 /

-0.47 (-2.13%)

Hot Stocks
Rubius Therapeutics appoints Dannielle Appelhans as COO » 08:09
07/29/21
07/29
08:09
07/29/21
08:09
RUBY

Rubius Therapeutics

$22.71 /

+2.02 (+9.76%)

, NVS

Novartis

$91.90 /

+0.605 (+0.66%)

Rubius Therapeutics…

Rubius Therapeutics (RUBY) announced the appointment of Dannielle Appelhans as chief operating officer, effective August 9, 2021. She will oversee corporate strategy and technical operations. Most recently, Ms. Appelhans served as senior vice president of technical operations and chief technical officer at Novartis Gene Therapies (NVS), where she oversaw late-stage development, clinical and commercial manufacturing, supply chain and all supporting operational functions for the gene therapy unit and AAV portfolio.

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$22.71 /

+2.02 (+9.76%)

NVS Novartis
$91.90 /

+0.605 (+0.66%)

RUBY Rubius Therapeutics
$22.71 /

+2.02 (+9.76%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
NVS Novartis
$91.90 /

+0.605 (+0.66%)

07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
07/22/21 Deutsche Bank
Novartis downgraded to Hold from Buy at Deutsche Bank
07/12/21 SVB Leerink
Molecular Partners assumed with an Outperform at SVB Leerink
RUBY Rubius Therapeutics
$22.71 /

+2.02 (+9.76%)

NVS Novartis
$91.90 /

+0.605 (+0.66%)

  • 17
    Mar
NVS Novartis
$91.90 /

+0.605 (+0.66%)

RUBY Rubius Therapeutics
$22.71 /

+2.02 (+9.76%)

NVS Novartis
$91.90 /

+0.605 (+0.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.